Janus Henderson rolls out global life sciences fund
The new offering aims to outperform the MSCI World Health Care Index
The new offering aims to outperform the MSCI World Health Care Index
|
|
Stonehage Fleming’s Gerrit Smit discusses the fourth industrial revolution, the reopening of China and currency movements
|
|
Polar Capital’s Deane Donnigan tells Portfolio Adviser how she moved from clinical pharmacist to fund manager
|
|
Manager of the PGIM Jennison Global Equity Opportunities Fund discusses how last year’s valuation reset has created a more fertile hunting ground for equities
|
|
Pictet Positive Change manager Evgenia Molotova and her team look to identify companies with the skill, balance sheet and will to change
|
|
Non-specialist investors flooding into and out of the latest fashionable investment idea can be as much an opportunity as a threat
|
|
The differing attractions of the pioneers, enablers and adopters of genetic sequencing
|
|
Average 12-month share price return of 5.4% masks a significant dispersion
|
|
Paul O’Connor of Janus Henderson and T Rowe Price’s Eric Papesh give their views on the prospects for American assets
|
|
This inherently innovative but sometimes esoteric sector has a lot to offer but market conditions are getting choppy
|
|
Investing through a thematic lens is vital if we are to realise a sustainable world. Portfolio Adviser’s sister publication ESG Clarity talks to experts about the challenges and opportunities in five key areas
|
|
While US bonds, healthcare and Latin America deliver the only bright spots
|
|